Cargando…

CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant

Fungal CYP51A (14α-sterol demethylase) is the target of an azole antifungal, voriconazole (VCZ), which also partially inhibits human CYP51A1. Hepatotoxicity is a common adverse effect of azoles, which is reported to be caused by altered gene expressions secondary to cholesterol synthesis inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Takuto, Smith, Angela R., Jacobson, Pamala A., Alharbi, Abeer F., Fisher, James, Rubin, Nathan T., Kirstein, Mark N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561836/ https://www.ncbi.nlm.nih.gov/pubmed/33560212 http://dx.doi.org/10.5414/CP203920

Ejemplares similares

Voriconazole: Hepatotoxicity: case report
Publicado: (2021)

Voriconazole-Induced Cholestatic Hepatotoxicity in an Immune Competent Patient
por: Mohammed, Yaser, et al.
Publicado: (2022)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Voriconazole-Induced Hepatotoxicity Presenting With Severe Hepatic Encephalopathy After Liver Transplantation
por: Tasleem, Syed Haris, et al.
Publicado: (2019)

Genetic Variation in Plant CYP51s Confers Resistance against Voriconazole, a Novel Inhibitor of Brassinosteroid-Dependent Sterol Biosynthesis
por: Rozhon, Wilfried, et al.
Publicado: (2013)

Evaluation of mRNA Expression Levels of cyp51A and mdr1, Candidate Genes for Voriconazole Resistance in Aspergillus flavus
por: Fattahi, Azam, et al.
Publicado: (2015)

A 23 bp cyp51A Promoter Deletion Associated With Voriconazole Resistance in Clinical and Environmental Isolates of Neocosmospora keratoplastica
por: James, Jasper Elvin, et al.
Publicado: (2020)

Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation
por: García-García, Irene, et al.
Publicado: (2021)

Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed‐Effects Analysis
por: Jaber, Mutaz M., et al.
Publicado: (2022)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Voriconazole-Induced Hepatotoxicity in a Patient with Pulmonary Aspergillosis: A Case Report
por: Gu, Li, et al.
Publicado: (2023)

Selection of Aspergillus fumigatus isolates carrying the G448S substitution in CYP51A gene after long-term treatment with voriconazole in an immunocompromised patient
por: Pontes, Laís, et al.
Publicado: (2022)

Polymorphisms of CYP51A1 from Cholesterol Synthesis: Associations with Birth Weight and Maternal Lipid Levels and Impact on CYP51 Protein Structure
por: Lewińska, Monika, et al.
Publicado: (2013)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole
por: Teng, Guo-Jie, et al.
Publicado: (2020)

An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol
por: Kunitomi, Akane, et al.
Publicado: (2018)

Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation
por: Chen, Xiao, et al.
Publicado: (2021)

Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies
por: Taghvaye-masoumi, Hamidreza, et al.
Publicado: (2021)

Voriconazole as a secondary prophylaxis for cryptococcal meningitis during hematopoietic stem cell transplantation
por: Kashima, Emiko, et al.
Publicado: (2021)

Occurrence of CYP2B6 516G>T polymorphism in patients with ARV‐associated hepatotoxicity
por: Singh, HariOm, et al.
Publicado: (2019)

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients
por: Li, Zi-Wei, et al.
Publicado: (2017)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children
por: Chen, Juan, et al.
Publicado: (2022)

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity
por: Franco, Caio H., et al.
Publicado: (2020)

Analysis of Cyp51 protein sequences shows 4 major Cyp51 gene family groups across fungi
por: Celia-Sanchez, Brandi N, et al.
Publicado: (2022)

Pharmacogenomics of COVID-19 therapies
por: Takahashi, Takuto, et al.
Publicado: (2020)

Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis
por: Agrawal, Vaibhav, et al.
Publicado: (2020)

Evaluation of Selected CYP51A1 Polymorphisms in View of Interactions with Substrate and Redox Partner
por: Režen, Tadeja, et al.
Publicado: (2017)

NAT2 and CYP2E1 polymorphisms and antituberculosis drug‐induced hepatotoxicity in Peruvian patients
por: Jaramillo‐Valverde, Luis, et al.
Publicado: (2022)

Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children
por: Espinoza, N., et al.
Publicado: (2019)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

1733. Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much Is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?
por: Hadjivassiliou, Giorgos, et al.
Publicado: (2019)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Point Mutations in the 14-α Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in Aspergillus flavus
por: Lucio, Jose, et al.
Publicado: (2020)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

Voriconazole-Induced Hepatotoxicity Resolved after Switching to Amphotericin B in Fusarium dimerum Central Line-Associated Bloodstream Infection
por: Alshaya, Omar A., et al.
Publicado: (2021)

Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017)

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021)

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
por: Takahashi, Takuto, et al.
Publicado: (2022)

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
por: Muhareb, Amin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gs4fba6tlj26oc35019fnpvssh